Litcius/Paper detail

CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities

Joseph W. Fischer, Nirjal Bhattarai

2021Frontiers in Immunology104 citationsDOIOpen Access PDF

Abstract

Engineered T cell therapies such as chimeric antigen receptor (CAR) expressing T cells (CAR-T cells) have great potential to treat many human diseases; however, inflammatory toxicities associated with these therapies present safety risks and can greatly limit its widespread use. This article briefly reviews our current understanding of mechanisms for inflammatory toxicities during CAR T-cell therapy, current strategies for management and mitigation of these risks and highlights key areas of knowledge gap for future research.

Topics & Concepts

Chimeric antigen receptorMechanism (biology)CAR T-cell therapyMedicineCell therapyT cellRisk analysis (engineering)ImmunologyCellBiologyImmune systemEpistemologyGeneticsPhilosophyCAR-T cell therapy researchNanowire Synthesis and Applications
CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities | Litcius